Condition: Multiple Myeloma · Sponsor: AstraZeneca
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Duarte, California, United States | Recruiting |
| Research Site | Irvine, California, United States | Recruiting |
| Research Site | Atlanta, Georgia, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Ann Arbor, Michigan, United States | Recruiting |
| Research Site | St Louis, Missouri, United States | Withdrawn |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Research Site | Fairfax, Virginia, United States | Recruiting |
| Research Site | Fitzroy, Australia | Recruiting |
| Research Site | Melbourne, Australia | Recruiting |
| Research Site | Nedlands, Australia | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06106945